John Mandeli

3.0k total citations
82 papers, 2.2k citations indexed

About

John Mandeli is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, John Mandeli has authored 82 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Oncology, 17 papers in Molecular Biology and 14 papers in Immunology. Recurrent topics in John Mandeli's work include Ovarian cancer diagnosis and treatment (11 papers), Immunotherapy and Immune Responses (10 papers) and Hepatocellular Carcinoma Treatment and Prognosis (7 papers). John Mandeli is often cited by papers focused on Ovarian cancer diagnosis and treatment (11 papers), Immunotherapy and Immune Responses (10 papers) and Hepatocellular Carcinoma Treatment and Prognosis (7 papers). John Mandeli collaborates with scholars based in United States, Spain and Australia. John Mandeli's co-authors include Jonathan D. Schwartz, Myron Schwartz, Max W. Sung, Deborah Lehrer, James F. Holland, Alec Goldenberg, E Popa, Jennifer J. Knox, E. Cohen and Robert S. Brown and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Lancet and Journal of Clinical Oncology.

In The Last Decade

John Mandeli

80 papers receiving 2.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
John Mandeli United States 24 659 608 591 323 322 82 2.2k
David Ho Hong Kong 21 1.1k 1.6× 1.0k 1.7× 607 1.0× 643 2.0× 255 0.8× 35 2.3k
Peter Büchler Germany 29 988 1.5× 1.3k 2.1× 330 0.6× 691 2.1× 276 0.9× 68 2.9k
Shuichi Mitsunaga Japan 28 1.0k 1.6× 544 0.9× 407 0.7× 318 1.0× 308 1.0× 125 2.5k
Anne M. Noonan United States 27 1.3k 1.9× 561 0.9× 185 0.3× 360 1.1× 354 1.1× 117 2.1k
Laura W. Goff United States 21 1.0k 1.5× 742 1.2× 347 0.6× 326 1.0× 118 0.4× 77 2.0k
Eli Avisar United States 19 1.4k 2.1× 303 0.5× 385 0.7× 567 1.8× 155 0.5× 72 2.2k
Jianmin Xu China 26 1.2k 1.8× 845 1.4× 468 0.8× 628 1.9× 301 0.9× 139 2.4k
Luca Faloppi Italy 25 807 1.2× 580 1.0× 457 0.8× 601 1.9× 138 0.4× 92 1.8k
Giuseppe Perrone Italy 27 1.2k 1.8× 866 1.4× 145 0.2× 563 1.7× 304 0.9× 122 2.6k
Viktória László Hungary 29 715 1.1× 834 1.4× 142 0.2× 372 1.2× 173 0.5× 70 2.3k

Countries citing papers authored by John Mandeli

Since Specialization
Citations

This map shows the geographic impact of John Mandeli's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John Mandeli with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John Mandeli more than expected).

Fields of papers citing papers by John Mandeli

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John Mandeli. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John Mandeli. The network helps show where John Mandeli may publish in the future.

Co-authorship network of co-authors of John Mandeli

This figure shows the co-authorship network connecting the top 25 collaborators of John Mandeli. A scholar is included among the top collaborators of John Mandeli based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John Mandeli. John Mandeli is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kyi, Chrisann, Vladimir Roudko, Rachel Lubong Sabado, et al.. (2018). Therapeutic Immune Modulation against Solid Cancers with Intratumoral Poly-ICLC: A Pilot Trial. Clinical Cancer Research. 24(20). 4937–4948. 97 indexed citations
2.
Kenny, Timothy C., Hank Schmidt, Kerin B. Adelson, et al.. (2017). Patient-derived Interstitial Fluids and Predisposition to Aggressive Sporadic Breast Cancer through Collagen Remodeling and Inactivation of p53. Clinical Cancer Research. 23(18). 5446–5459. 17 indexed citations
3.
Ma, Ge, Neil Gildener‐Leapman, Samuel Eisenstein, et al.. (2015). Myeloid-Derived Suppressor Cells as an Immune Parameter in Patients with Concurrent Sunitinib and Stereotactic Body Radiotherapy. Clinical Cancer Research. 21(18). 4073–4085. 90 indexed citations
4.
Wang, Qin, Wei Luan, Leslie Warren, et al.. (2015). Prognostic Role of Immune Cells in Hepatitis B-associated Hepatocellular Carcinoma Following Surgical Resection Depends on Their Localization and Tumor Size. Journal of Immunotherapy. 39(1). 36–44. 13 indexed citations
5.
Liu, Xiaomei, Enrique Carrillo de Santa Pau, Pamela D. Unger, et al.. (2012). KLF6 Loss of Function in Human Prostate Cancer Progression Is Implicated in Resistance to Androgen Deprivation. American Journal Of Pathology. 181(3). 1007–1016. 23 indexed citations
6.
Chen, Li, Tiangui Huang, Marcia Meseck, et al.. (2007). Rejection of Metastatic 4T1 Breast Cancer by Attenuation of Treg Cells in Combination With Immune Stimulation. Molecular Therapy. 15(12). 2194–2202. 61 indexed citations
7.
Ishii, Yuki, James V. Alvarez, David A. Frank, et al.. (2006). Cyclin D1 Overexpression and Response to Bortezomib Treatment in a Breast Cancer Model. JNCI Journal of the National Cancer Institute. 98(17). 1238–1247. 48 indexed citations
8.
Höchster, Howard S., Elizabeth R. Plimack, John Mandeli, et al.. (2005). Prolonged topotecan infusion with cisplatin in the first-line treatment of ovarian cancer: An NYGOG and ECOG study. Gynecologic Oncology. 100(2). 324–329. 8 indexed citations
9.
Nezhat, Farr, Scott Wadler, Franco M. Muggia, et al.. (2004). Phase II trial of the combination of bryostatin-1 and cisplatin in advanced or recurrent carcinoma of the cervix: a New York Gynecologic Oncology Group study. Gynecologic Oncology. 93(1). 144–148. 32 indexed citations
10.
Holland, James F., et al.. (2001). Stable lower PAR expression decreased DU145 prostate cancer cell growth in SCID mice. The Prostate. 49(3). 200–207. 8 indexed citations
11.
12.
Wadler, Scott, Edward L. Schwartz, Hilda Haynes, et al.. (1997). All-trans retinoic acid and interferon-?-2a in patients with metastatic or recurrent carcinoma of the uterine cervix. Cancer. 79(8). 1574–1580. 16 indexed citations
13.
Speyer, James L., John Mandeli, Howard S. Höchster, et al.. (1995). A Phase I Trial of Cyclosphosphamide and Carboplatinum Combined with Interleukin-3 in Women with Advanced-Stage Ovarian Cancer. Gynecologic Oncology. 56(3). 387–394. 8 indexed citations
14.
Puolakkainen, Pauli, et al.. (1995). Increase of Plasma Transforming Growth Factor Beta (TGFβ) During Immunotherapy with IL-2. Cancer Investigation. 13(6). 583–589. 7 indexed citations
15.
Dottino, Peter R., et al.. (1994). Growth Factor Expression in Normal Peritoneum of Patients with Gynecologic Carcinoma. Gynecologic Oncology. 55(2). 190–197. 4 indexed citations
16.
Schiavi, Raul C., Daniel White, John Mandeli, & Patricia Schreiner-Engel. (1993). Hormones and nocturnal penile tumescence in healthy aging men. Archives of Sexual Behavior. 22(3). 207–215. 39 indexed citations
17.
Doody, Jacqueline, et al.. (1991). Role of prolactin in growth of the rat mammary tumor MTW9. International Journal of Cancer. 48(1). 109–112. 4 indexed citations
18.
Paciucci, Paolo Alberto, John Mandeli, Leslie Oleksowicz, Franco Ameglio, & James F. Holland. (1990). Thrombocytopenia during immunotherapy with interleukin-2 by constant infusion. The American Journal of Medicine. 89(3). 308–312. 31 indexed citations
19.
Siris, Samuel G., et al.. (1989). Comparison of 6- with 9-week trials of adjunctive imipramine in postpsychotic depression. Comprehensive Psychiatry. 30(6). 483–488. 1 indexed citations
20.
Mandeli, John & Walter T. Fédérer. (1975). Complete Sets of Orthogonal F-Squares of Prime Power Order with Differing Numbers of Symbols. eCommons (Cornell University). 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by David Ho Breakdown of academic impact, for papers by Peter Büchler Breakdown of academic impact, for papers by Shuichi Mitsunaga Breakdown of academic impact, for papers by Anne M. Noonan Breakdown of academic impact, for papers by Laura W. Goff Breakdown of academic impact, for papers by Eli Avisar Breakdown of academic impact, for papers by Jianmin Xu Breakdown of academic impact, for papers by Luca Faloppi Breakdown of academic impact, for papers by Giuseppe Perrone Breakdown of academic impact, for papers by Viktória László
Rankless by CCL
2026